Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

The supply shortage and high costs of GLP-1 weight loss drugs have created an opportunity for compounded GLP-1 treatments to ...

A recent study found that over a third of websites selling compounded diabetes and weight loss medications, such as Ozempic and Wegovy, falsely claim they are FDA-approved.

Wegovy and Ozempic remain on the FDA's shortages list, despite strenuous efforts ... professionals turning to unapproved versions of GLP-1 drugs as an option for weight loss, saying: "This can ...

It's possible that Alzheimer's disease could be added to the lengthening list of ... injectable GLP-1 agonist liraglutide in people with early-stage Alzheimer's has shown that the drug was able ...

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

Novo Nordisk boasts 45 million customers using their drug Ozempic, which has caused a revolution in weight-loss treatment.

Novo Nordisk boasts 45 million customers using its drug, which has caused a revolution in weight-loss treatment. But competitors are nipping at its heels.

Telehealth stock Hims & Hers ( HIMS) spiked more than 24% in trading Thursday, days after its Super Bowl ad promoting cheaper GLP-1 weight-loss drugs sparked controversy.

The Super Bowl is not just the biggest game of the year for football fans, but it is also one of advertising’s biggest nights. Therefore, the ...

Last year was a pivotal year for the pharmaceutical industry. Under the IRA’s Medicare Drug Price Negotiation Program (the ...

Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.